abgn-107
mAbexperimentalADC
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01466569)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297683 ↗
Also known as
- abgn-107
- abgn-7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02908451 | Phase 1 | Apr 24, 2017 | AltruBio, University of California, San Francisco |
| NCT01466569 | Phase 1 | Nov 1, 2011 | AltruBio, Mackay Medical College, National Taiwan University, Temple University, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AltruBio | For profit | 2 | 2 | 1 | 2011 |
| Mackay Medical College | Academic/Hospital | 1 | 0 | 1 | 2011 |
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2011 |
6 organizations
Page 1 / 1